Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishThe tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
Cortegiani, A., Ippolito, M., Ingoglia, G., & Einav, S. (2020). Chloroquine for COVID-19: rationale, facts, hopes. CRITICAL CARE, 24(1).
| Data di pubblicazione: | 2020 |
| Titolo: | Chloroquine for COVID-19: rationale, facts, hopes |
| Autori: | |
| Citazione: | Cortegiani, A., Ippolito, M., Ingoglia, G., & Einav, S. (2020). Chloroquine for COVID-19: rationale, facts, hopes. CRITICAL CARE, 24(1). |
| Rivista: | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1186/s13054-020-02932-4 |
| Abstract: | The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19? |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| s13054-020-02932-4.pdf | Versione Editoriale | Open Access Visualizza/Apri |
Copyright © 2021